China Medical System Holdings (HK:0867) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
China Medical System Holdings Limited has announced the approval of Lumeblue®, an innovative diagnostic drug for improving colorectal lesion detection during colonoscopies, by China’s National Medical Products Administration. Lumeblue®, which utilizes patented MMX technology for targeted delivery, has shown significant improvement in lesion detection rates in Phase III trials. The company, which acquired exclusive licensing rights in December 2020, plans to expedite the commercialization of the drug in China, following its successful launch in the European Union.
For further insights into HK:0867 stock, check out TipRanks’ Stock Analysis page.
